Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 7th
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 7thNew Haven, CT 06511
Shalin Kothari, MD
Hematology & Oncology, Leukemia & Lymphoma
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine
Biography
Shalin Kothari, MD, is a hematologist who treats patients with Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia.
Dr. Kothari’s research focuses on treatments for various aggressive forms of B-cell lymphomas, such as mantle cell lymphomas and diffuse large B-cell lymphomas. This disease causes either circulating lymphoma cells in the blood and/or enlarged lymph nodes due to a rapid accumulation of lymphoma cells.
He is a Lymphoma Research Foundation (LRF) Scholar and an inductee of the ASH Advocacy Leadership Institute and the Gold Humanism Honor Society. Most recently, Dr. Kothari was awarded the Gerald L. Logue Memorial Award for Outstanding Performance in Hematology/Oncology and a research funding award from The DeLuca Center for Innovation in Hematology Research.
Dr. Kothari is an assistant professor of medicine (hematology) at Yale School of Medicine.
Titles
- Assistant Professor of Medicine (Hematology)
- Clinician Lead, Cancer Biology Training Program
- Core Faculty, Medical Oncology and Hematology Fellowship Program
Education & Training
- FellowRoswell Park Comprehensive Cancer Center (2019)
- Internal Medicine ResidencySUNY Upstate Medical University (2016)
- Senior Research AssociateUniversity of Louisville (2013)
- MDGujarat University
Languages Spoken
- English
- ગુજરાતી (Gujarati)
- हिन्दी (Hindi)
Additional Information
Honors & Recognitions
- Member of the Mantle Cell Lymphoma Consortium: Lymphoma Research Foundation (2021)
- The DeLuca Center for Innovation in Hematology Career Development Award: (2020)
- Gerald L. Logue Memorial Award for Outstanding Performance in Hematology/Oncology: (2019)
- American Society of Hematology (ASH) Abstract Achievement Award: (2018)
- American Society of Hematology (ASH) Advocacy Leadership Institute: (2018)
- Lymphoma Research Foundation (LRF) Scholar: (2018)
- Arnold P. Gold Humanism Award in Medicine: (2017)
Professional Service
- VuMedi (2023 - Present): Presenter/Speaker
- Institutional Review Board (2022 - Present): Member
- American Society of Hematology (2022 - Present): 603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis Symposia: Lymphoid Oncogenesis: Basic Program: Oral and Poster Abstracts Type: Oral Hematology Disease Topics & Pathways: Fundamental Science, Research, Lymphoid Leukemias, ALL, apoptosis, Lymphomas, non-Hodgkin lymphoma, Translational Research, B Cell lymphoma, Genetic Disorders, genomics, T Cell lymphoma, hematopoiesis, Diseases, immune mechanism, aggressive lymphoma, immunology, Lymphoid Malignancies, metabolism, computational biology, Biological Processes, Technology and Procedures, gene editing, molecular biology, Study Population, multi-systemic interactions, Human, pathogenesis, Animal model Monday, December 12, 2022: 10:30 AM-12:00 PM 208-210 (Ernest N. Morial Convention Center) Moderators: Paolo Ghia, MD, PhD, Universita' Vita-Salute San Raffaele C.F. 97187560152 and Shalin K. Kothari, MD, Center of Molecular and Cellular Oncology and Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
- Lymphoma Research Foundation (LRF) Lymphoma Scientific Research Mentoring Program (LSRMP) – Clinical and Translational Track grants (2020): External Reviewer
- WNPR Radio Show - Yale Cancer Center Answers (2020): Invited Guest at the WNPR Radio Show - “Early-phase clinical trials and Lymphoma” – Yale Cancer Center Answers
- PA Program Lecture- Lymphomas: Hodgkin Lymphoma and CLL (2020 - Present): Presenter/Speaker
- 4th Annual Hematologic Malignancies Symposium (2019): Reviewer
- Hematology and Medical Oncology Fellowship: Interview Committee (2019 - Present): Interviewer
- Yale Medical School Core Lecture Series (2019 - Present): Presenter/Speaker
- Clinical Lymphoma, Myeloma and Leukemia (2019 - Present): Reviewer
Publications
- Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.
- Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, DOI: 10.1182/bloodadvances.2024013791.
- Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
- Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery 2024, 14: 1577-1580. PMID: 39228298, DOI: 10.1158/2159-8290.cd-24-0644.
- Warner J, Bakow B, Brown A, Choe J, Fan E, Ganta T, Glover M, Hadfield M, Hilton C, Khaki A, Kothari S, Lythgoe M, Nagpal S, Nguyen R, Noyd D, Riaz I, Rooney M, Sethi T, Singhi E, Rubinstein S. Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. Journal Of Clinical Oncology 2024, 42: 11079-11079. DOI: 10.1200/jco.2024.42.16_suppl.11079.
- Jain S, Zauderer M, Sethi T, Schoen M, Rubinstein S, Nguyen R, Nagpal S, Mohan S, Madireddy S, Lythgoe M, Liang W, Kulkarni A, Kothari S, Hilal T, Hadfield M, Goyal G, Ganta T, Dholaria B, Brown A, Warner J. Evaluation of the study of control arms in randomized clinical trials of cancer. Journal Of Clinical Oncology 2024, 42: 11023-11023. DOI: 10.1200/jco.2024.42.16_suppl.11023.
- Cosgun K, Jumaa H, Robinson M, Klemm L, Oulghazi S, Fonseca-Arce D, Xu L, Xiao G, Khanduja D, Chan L, Lee J, Kume K, Song J, Chan W, Chen J, Taketo M, Kothari S. Dependence of lymphopoiesis on efficient β-catenin degradation. The Journal Of Immunology 2024, 212: 1195_4936-1195_4936. DOI: 10.4049/jimmunol.212.supp.1195.4936.
- Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.
- Ketzer F, Klemm L, Robinson M, Loucks C, Arce D, Cosgun K, Kothari S, Müschen M. Separation of B- and T-Cell-Specific Signaling Molecules Prevents Oncogenic Transformation in Lymphoid Malignancies. Blood 2023, 142: 1396. DOI: 10.1182/blood-2023-189221.
- Khanduja D, Robinson M, Arce D, Klemm L, Leveille E, Kothari S, Caeser R, Hodson D, Müschen M. Genetic Knockin Approaches to Reconstructing DLBCL-Subtypes from Human Germinal Center B-Cells. Blood 2023, 142: 1627. DOI: 10.1182/blood-2023-190634.
- Li Q, Robinson M, Leveille E, Zhang C, Sun R, Cheng Z, Kume K, Cosgun K, Kothari S, Khanduja D, Nakada D, Müschen M. Computational Discovery and Validation of NAD+ Biosynthesis As Unique Vulnerability in B-Lymphoid Malignancies. Blood 2023, 142: 418. DOI: 10.1182/blood-2023-190269.
- Cosgun K, Robinson M, Oulghazi S, Xu L, Xiao G, Chan L, Lee J, Kume K, Leveille E, Arce D, Khanduja D, Feldhahn N, Song J, Chan W, Chen J, Taketo M, Schjerven H, Jellusova J, Kothari S, Davids M, Müschen M. Repurposing GSK3B Small Molecule Inhibitors for Refractory Lymphoid Malignancies. Blood 2023, 142: 2818. DOI: 10.1182/blood-2023-190522.
- Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.
- Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.
- Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
- Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.
- Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. The Oncologist 2023, 28: 246-251. PMID: 36651837, PMCID: PMC10020806, DOI: 10.1093/oncolo/oyac245.
- Leveille E, Kothari S, Müschen M. Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies. Blood Cancer Discovery 2022, 4: 8-11. PMID: 36534735, PMCID: PMC9816816, DOI: 10.1158/2643-3230.bcd-22-0180.
- Epperla N, Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series. Blood 2022, 140: 3839-3841. DOI: 10.1182/blood-2022-157105.
- Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, Sheets J, Weiner DM, Geethakumari P, Kandarpa M, Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover N, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Advances 2022, 7: 88-91. PMID: 36269847, PMCID: PMC9827027, DOI: 10.1182/bloodadvances.2022008634.
- Shah H, Vardell V, Zacholski E, Fegley A, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Aqeel S, Borogovac A, Macdougall K, Kothari S, Kress A, Modi D, Travers E, Chilakamarri N, Brem E, Stephens D, Hu B, Fitzgerlad L, Wagner C, Ermann D. P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma. HemaSphere 2022, 6: 47-48. PMCID: PMC9621536, DOI: 10.1097/01.hs9.0000890976.21005.88.
- Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.
- Di M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis R, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.
- Ermann D, Vardell V, Zacholski E, Fegley A, Modi D, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Aqeel S, Borogovac A, MacDougall K, Kothari S, Kress A, Travers E, Chilakamarri N, Brem E, Fitzgerald L, Wagner C, Hu B, Stephens D, Shah H. P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA. HemaSphere 2022, 6: 969-970. PMCID: PMC9431349, DOI: 10.1097/01.hs9.0000847184.45889.7a.
- Güney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Boué DR, Schafernak K, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen A, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW. A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Advances 2022, 6: 3189-3193. PMID: 35157770, PMCID: PMC9131901, DOI: 10.1182/bloodadvances.2021006018.
- Zayac A, Landsburg D, Hughes M, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. Blood 2021, 138: 455. DOI: 10.1182/blood-2021-144308.
- Li P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, Xu ML. Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases. Frontiers In Oncology 2021, 11: 730503. PMID: 34589432, PMCID: PMC8474637, DOI: 10.3389/fonc.2021.730503.
- Mato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.
- Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
- Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.
- Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
- Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, Barth M, Hernandez‐Ilizaliturri F. Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. EJHaem 2020, 1: 122-132. PMID: 33073261, PMCID: PMC7566777, DOI: 10.1002/jha2.2.
- Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsTorka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances 2020, 4: 253-262. PMID: 31945157, PMCID: PMC6988401, DOI: 10.1182/bloodadvances.2019000875.
- Torka, P, Mavis, C, Kothari, S, Belliotti, Gu J, Sundaram S, Barth M, Hernandez-Ilizaliturri FJ. eJHaem. April 2020; 1– 11. https://doi.org/10.1002/jha2.2
- Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.
- Kothari S, Hillengass J, McCarthy PL, Holstein SA. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter? Current Hematologic Malignancy Reports 2019, 14: 39-46. PMID: 30671912, DOI: 10.1007/s11899-019-0497-7.
- Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal Of Clinical Oncology 2019, 37: 471-480. PMID: 30615550, PMCID: PMC7554677, DOI: 10.1200/jco.18.00690.
- Kothari S, Mavis C, Gu J, Hernandez-Ilizaliturri F. Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models. Blood 2018, 132: 2942. DOI: 10.1182/blood-2018-99-116510.
- Kothari S, Li S, Medeiros L, Ayers E, Landsburg D, Bond D, Maddocks K, Giri A, Hess B, Pham L, Advani R, Liu Y, Barta S, Vose J, Churnetski M, Cohen J, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski A, Lee S, Hill B, Burns T, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri F, Torka P. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. Blood 2018, 132: 451. DOI: 10.1182/blood-2018-99-111530.
- Kothari S, Hernandez-Ilizaliturri F, Torka P. Striking a Happy Medium. Journal Of Clinical Oncology 2017, 35: jco.2017.73.983. PMID: 28682685, DOI: 10.1200/jco.2017.73.9839.
- Kothari S, Sharif-Tabrizi A, Attwood K, Lamonica D, Levine E, George S. Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment. Journal Of Clinical Oncology 2017, 35: e16513-e16513. DOI: 10.1200/jco.2017.35.15_suppl.e16513.
- DeFilippis AP, Chernyavskiy I, Amraotkar AR, Trainor PJ, Kothari S, Ismail I, Hargis CW, Korley FK, Leibundgut G, Tsimikas S, Rai SN, Bhatnagar A. Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. Journal Of Thrombosis And Thrombolysis 2016, 42: 61-76. PMID: 26510751, PMCID: PMC5403145, DOI: 10.1007/s11239-015-1292-5.
- Kothari S, Ud-Din N, Lisi M, Coyle T. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report. Journal Of Medical Case Reports 2016, 10: 176. PMID: 27301488, PMCID: PMC4908805, DOI: 10.1186/s13256-016-0963-y.
- Kothari S, Herzig G, Slone S, Herzig R. Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature. SpringerPlus 2013, 2: 49. PMID: 23476896, PMCID: PMC3586393, DOI: 10.1186/2193-1801-2-49.
- Arnold F, Kothari S, Harting J. Resistance To Acinetobacter Is Not Associated With Disposition Among Patients Leaving A Long-Term Acute-Care Facility. 2012, a6072-a6072. DOI: 10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6072.
Departments and Programs
Locations
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 7th
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 7thNew Haven, CT 06511
Biography
Shalin Kothari, MD, is a hematologist who treats patients with Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia.
Dr. Kothari’s research focuses on treatments for various aggressive forms of B-cell lymphomas, such as mantle cell lymphomas and diffuse large B-cell lymphomas. This disease causes either circulating lymphoma cells in the blood and/or enlarged lymph nodes due to a rapid accumulation of lymphoma cells.
He is a Lymphoma Research Foundation (LRF) Scholar and an inductee of the ASH Advocacy Leadership Institute and the Gold Humanism Honor Society. Most recently, Dr. Kothari was awarded the Gerald L. Logue Memorial Award for Outstanding Performance in Hematology/Oncology and a research funding award from The DeLuca Center for Innovation in Hematology Research.
Dr. Kothari is an assistant professor of medicine (hematology) at Yale School of Medicine.
Titles
- Assistant Professor of Medicine (Hematology)
- Clinician Lead, Cancer Biology Training Program
- Core Faculty, Medical Oncology and Hematology Fellowship Program
Education & Training
- FellowRoswell Park Comprehensive Cancer Center (2019)
- Internal Medicine ResidencySUNY Upstate Medical University (2016)
- Senior Research AssociateUniversity of Louisville (2013)
- MDGujarat University
Languages Spoken
- English
- ગુજરાતી (Gujarati)
- हिन्दी (Hindi)
Additional Information
Honors & Recognitions
- Member of the Mantle Cell Lymphoma Consortium: Lymphoma Research Foundation (2021)
- The DeLuca Center for Innovation in Hematology Career Development Award: (2020)
- Gerald L. Logue Memorial Award for Outstanding Performance in Hematology/Oncology: (2019)
- American Society of Hematology (ASH) Abstract Achievement Award: (2018)
- American Society of Hematology (ASH) Advocacy Leadership Institute: (2018)
- Lymphoma Research Foundation (LRF) Scholar: (2018)
- Arnold P. Gold Humanism Award in Medicine: (2017)
Professional Service
- VuMedi (2023 - Present): Presenter/Speaker
- Institutional Review Board (2022 - Present): Member
- American Society of Hematology (2022 - Present): 603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis Symposia: Lymphoid Oncogenesis: Basic Program: Oral and Poster Abstracts Type: Oral Hematology Disease Topics & Pathways: Fundamental Science, Research, Lymphoid Leukemias, ALL, apoptosis, Lymphomas, non-Hodgkin lymphoma, Translational Research, B Cell lymphoma, Genetic Disorders, genomics, T Cell lymphoma, hematopoiesis, Diseases, immune mechanism, aggressive lymphoma, immunology, Lymphoid Malignancies, metabolism, computational biology, Biological Processes, Technology and Procedures, gene editing, molecular biology, Study Population, multi-systemic interactions, Human, pathogenesis, Animal model Monday, December 12, 2022: 10:30 AM-12:00 PM 208-210 (Ernest N. Morial Convention Center) Moderators: Paolo Ghia, MD, PhD, Universita' Vita-Salute San Raffaele C.F. 97187560152 and Shalin K. Kothari, MD, Center of Molecular and Cellular Oncology and Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
- Lymphoma Research Foundation (LRF) Lymphoma Scientific Research Mentoring Program (LSRMP) – Clinical and Translational Track grants (2020): External Reviewer
- WNPR Radio Show - Yale Cancer Center Answers (2020): Invited Guest at the WNPR Radio Show - “Early-phase clinical trials and Lymphoma” – Yale Cancer Center Answers
- PA Program Lecture- Lymphomas: Hodgkin Lymphoma and CLL (2020 - Present): Presenter/Speaker
- 4th Annual Hematologic Malignancies Symposium (2019): Reviewer
- Hematology and Medical Oncology Fellowship: Interview Committee (2019 - Present): Interviewer
- Yale Medical School Core Lecture Series (2019 - Present): Presenter/Speaker
- Clinical Lymphoma, Myeloma and Leukemia (2019 - Present): Reviewer
Publications
- Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.
- Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, DOI: 10.1182/bloodadvances.2024013791.
- Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
- Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery 2024, 14: 1577-1580. PMID: 39228298, DOI: 10.1158/2159-8290.cd-24-0644.
- Warner J, Bakow B, Brown A, Choe J, Fan E, Ganta T, Glover M, Hadfield M, Hilton C, Khaki A, Kothari S, Lythgoe M, Nagpal S, Nguyen R, Noyd D, Riaz I, Rooney M, Sethi T, Singhi E, Rubinstein S. Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. Journal Of Clinical Oncology 2024, 42: 11079-11079. DOI: 10.1200/jco.2024.42.16_suppl.11079.
- Jain S, Zauderer M, Sethi T, Schoen M, Rubinstein S, Nguyen R, Nagpal S, Mohan S, Madireddy S, Lythgoe M, Liang W, Kulkarni A, Kothari S, Hilal T, Hadfield M, Goyal G, Ganta T, Dholaria B, Brown A, Warner J. Evaluation of the study of control arms in randomized clinical trials of cancer. Journal Of Clinical Oncology 2024, 42: 11023-11023. DOI: 10.1200/jco.2024.42.16_suppl.11023.
- Cosgun K, Jumaa H, Robinson M, Klemm L, Oulghazi S, Fonseca-Arce D, Xu L, Xiao G, Khanduja D, Chan L, Lee J, Kume K, Song J, Chan W, Chen J, Taketo M, Kothari S. Dependence of lymphopoiesis on efficient β-catenin degradation. The Journal Of Immunology 2024, 212: 1195_4936-1195_4936. DOI: 10.4049/jimmunol.212.supp.1195.4936.
- Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.
- Ketzer F, Klemm L, Robinson M, Loucks C, Arce D, Cosgun K, Kothari S, Müschen M. Separation of B- and T-Cell-Specific Signaling Molecules Prevents Oncogenic Transformation in Lymphoid Malignancies. Blood 2023, 142: 1396. DOI: 10.1182/blood-2023-189221.
- Khanduja D, Robinson M, Arce D, Klemm L, Leveille E, Kothari S, Caeser R, Hodson D, Müschen M. Genetic Knockin Approaches to Reconstructing DLBCL-Subtypes from Human Germinal Center B-Cells. Blood 2023, 142: 1627. DOI: 10.1182/blood-2023-190634.
- Li Q, Robinson M, Leveille E, Zhang C, Sun R, Cheng Z, Kume K, Cosgun K, Kothari S, Khanduja D, Nakada D, Müschen M. Computational Discovery and Validation of NAD+ Biosynthesis As Unique Vulnerability in B-Lymphoid Malignancies. Blood 2023, 142: 418. DOI: 10.1182/blood-2023-190269.
- Cosgun K, Robinson M, Oulghazi S, Xu L, Xiao G, Chan L, Lee J, Kume K, Leveille E, Arce D, Khanduja D, Feldhahn N, Song J, Chan W, Chen J, Taketo M, Schjerven H, Jellusova J, Kothari S, Davids M, Müschen M. Repurposing GSK3B Small Molecule Inhibitors for Refractory Lymphoid Malignancies. Blood 2023, 142: 2818. DOI: 10.1182/blood-2023-190522.
- Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.
- Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.
- Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.
- Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.
- Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. The Oncologist 2023, 28: 246-251. PMID: 36651837, PMCID: PMC10020806, DOI: 10.1093/oncolo/oyac245.
- Leveille E, Kothari S, Müschen M. Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies. Blood Cancer Discovery 2022, 4: 8-11. PMID: 36534735, PMCID: PMC9816816, DOI: 10.1158/2643-3230.bcd-22-0180.
- Epperla N, Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series. Blood 2022, 140: 3839-3841. DOI: 10.1182/blood-2022-157105.
- Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, Sheets J, Weiner DM, Geethakumari P, Kandarpa M, Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover N, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Advances 2022, 7: 88-91. PMID: 36269847, PMCID: PMC9827027, DOI: 10.1182/bloodadvances.2022008634.
- Shah H, Vardell V, Zacholski E, Fegley A, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Aqeel S, Borogovac A, Macdougall K, Kothari S, Kress A, Modi D, Travers E, Chilakamarri N, Brem E, Stephens D, Hu B, Fitzgerlad L, Wagner C, Ermann D. P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma. HemaSphere 2022, 6: 47-48. PMCID: PMC9621536, DOI: 10.1097/01.hs9.0000890976.21005.88.
- Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.
- Di M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis R, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.
- Ermann D, Vardell V, Zacholski E, Fegley A, Modi D, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Aqeel S, Borogovac A, MacDougall K, Kothari S, Kress A, Travers E, Chilakamarri N, Brem E, Fitzgerald L, Wagner C, Hu B, Stephens D, Shah H. P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA. HemaSphere 2022, 6: 969-970. PMCID: PMC9431349, DOI: 10.1097/01.hs9.0000847184.45889.7a.
- Güney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Boué DR, Schafernak K, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen A, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW. A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Advances 2022, 6: 3189-3193. PMID: 35157770, PMCID: PMC9131901, DOI: 10.1182/bloodadvances.2021006018.
- Zayac A, Landsburg D, Hughes M, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. Blood 2021, 138: 455. DOI: 10.1182/blood-2021-144308.
- Li P, Biancon G, Patel T, Pan Z, Kothari S, Halene S, Prebet T, Xu ML. Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases. Frontiers In Oncology 2021, 11: 730503. PMID: 34589432, PMCID: PMC8474637, DOI: 10.3389/fonc.2021.730503.
- Mato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.
- Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
- Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.
- Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
- Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, Barth M, Hernandez‐Ilizaliturri F. Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. EJHaem 2020, 1: 122-132. PMID: 33073261, PMCID: PMC7566777, DOI: 10.1002/jha2.2.
- Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsTorka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances 2020, 4: 253-262. PMID: 31945157, PMCID: PMC6988401, DOI: 10.1182/bloodadvances.2019000875.
- Torka, P, Mavis, C, Kothari, S, Belliotti, Gu J, Sundaram S, Barth M, Hernandez-Ilizaliturri FJ. eJHaem. April 2020; 1– 11. https://doi.org/10.1002/jha2.2
- Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.
- Kothari S, Hillengass J, McCarthy PL, Holstein SA. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter? Current Hematologic Malignancy Reports 2019, 14: 39-46. PMID: 30671912, DOI: 10.1007/s11899-019-0497-7.
- Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal Of Clinical Oncology 2019, 37: 471-480. PMID: 30615550, PMCID: PMC7554677, DOI: 10.1200/jco.18.00690.
- Kothari S, Mavis C, Gu J, Hernandez-Ilizaliturri F. Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models. Blood 2018, 132: 2942. DOI: 10.1182/blood-2018-99-116510.
- Kothari S, Li S, Medeiros L, Ayers E, Landsburg D, Bond D, Maddocks K, Giri A, Hess B, Pham L, Advani R, Liu Y, Barta S, Vose J, Churnetski M, Cohen J, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski A, Lee S, Hill B, Burns T, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri F, Torka P. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. Blood 2018, 132: 451. DOI: 10.1182/blood-2018-99-111530.
- Kothari S, Hernandez-Ilizaliturri F, Torka P. Striking a Happy Medium. Journal Of Clinical Oncology 2017, 35: jco.2017.73.983. PMID: 28682685, DOI: 10.1200/jco.2017.73.9839.
- Kothari S, Sharif-Tabrizi A, Attwood K, Lamonica D, Levine E, George S. Bone scan index at baseline as a tool for predicting hematologic toxicity in metastatic castration-resistant prostate cancer patients eligible for radium-223 treatment. Journal Of Clinical Oncology 2017, 35: e16513-e16513. DOI: 10.1200/jco.2017.35.15_suppl.e16513.
- DeFilippis AP, Chernyavskiy I, Amraotkar AR, Trainor PJ, Kothari S, Ismail I, Hargis CW, Korley FK, Leibundgut G, Tsimikas S, Rai SN, Bhatnagar A. Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. Journal Of Thrombosis And Thrombolysis 2016, 42: 61-76. PMID: 26510751, PMCID: PMC5403145, DOI: 10.1007/s11239-015-1292-5.
- Kothari S, Ud-Din N, Lisi M, Coyle T. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report. Journal Of Medical Case Reports 2016, 10: 176. PMID: 27301488, PMCID: PMC4908805, DOI: 10.1186/s13256-016-0963-y.
- Kothari S, Herzig G, Slone S, Herzig R. Multiple isolated extramedullary relapse of acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant: a case report and review of literature. SpringerPlus 2013, 2: 49. PMID: 23476896, PMCID: PMC3586393, DOI: 10.1186/2193-1801-2-49.
- Arnold F, Kothari S, Harting J. Resistance To Acinetobacter Is Not Associated With Disposition Among Patients Leaving A Long-Term Acute-Care Facility. 2012, a6072-a6072. DOI: 10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6072.
Departments and Programs
Locations
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 7th
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 7thNew Haven, CT 06511
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 7th
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 7thNew Haven, CT 06511